tamoxifen - CISMeF

Preferred Label : tamoxifen;

MeSH definition : One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.;

CISMeF synonym : savient brand of tamoxifen citrate;

MeSH hyponym : ici-46,474; ICI-47699; zitazonium; nolvadex; tamoxifen citrate; ICI-46474; soltamox; tomaxithen; ICI 47699; ICI47699; Novaldex; Citrate, Tamoxifen; ICI 46474; ICI46474; ICI 46,474; ICI46,474;

MeSH CAS label : ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)-;

MeSH Related Number : 10540-29-1 (Tamoxifen); 54965-24-1 (citrate); tamoxifen citrate; 7FRV7310N6;

Registry Number MeSH : 10540-29-1;

Related CAS MeSH : 7FRV7310N6 (Tamoxifen citrate);

Wikipedia link : https://en.wikipedia.org/wiki/Tamoxifen;

Codes EINECS : 234-118-0;

Is substance : O;

UNII : 094ZI81Y45;

InChIKey : NKANXQFJJICGDU-QPLCGJKRSA-N;

Details

Origin ID

D013629;

UMLS CUI

C0039286;

ATC code(s)
- tamoxifen [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- Tamoxifen poisoning (disorder) [SNOMED CT concept]
- tamoxifen [Substance BNPC]
False automatic mappings
- Antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified [ICD-10 Sub-category (who)]
- Poisoning by, adverse effect of and underdosing of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified [ICD-10 Sub-category]
Pharmacological action(s)
- antineoplastic agents, hormonal [MeSH Descriptor]
- bone density conservation agents [MeSH Descriptor]
- estrogen antagonists [MeSH Descriptor]
- selective estrogen receptor modulators [MeSH Descriptor]
Record concept(s)
- ICI-46474 [MeSH concept]
- ICI-47699 [MeSH concept]
- nolvadex [MeSH concept]
- soltamox [MeSH concept]
- tamoxifen [MeSH concept]
- tamoxifen citrate [MeSH concept]
- tomaxithen [MeSH concept]
- zitazonium [MeSH concept]
Related MeSH Supplementary Concept(s)
- (1-(4-dimethylaminoethoxy)phenyl)-1-(4-hydroxyphenyl)-2-bromo-2-phenylethylene [MeSH Supplementary Concept]
- 1,1-dichloro-2,3-diphenyl-2-(4-methoxyphenyl)cyclopropane [MeSH Supplementary Concept]
- 2-(4-(1-(4-hydroxyphenyl)-2-(4-isopropylphenyl)-1-butenyl)phenoxy)-N,N-dimethylethylamine [MeSH Supplementary Concept]
- 2-methyl-4-hydroxytamoxifen [MeSH Supplementary Concept]
- 3,4-dihydroxytamoxifen [MeSH Supplementary Concept]
- 3,4-dihydroxytamoxifen-o-quinone [MeSH Supplementary Concept]
- 4-(4-(2-(dimethylamino)ethoxy)phenyl)-3,4-diphenyl-2-(9beta-deoxyribofuranosyl-6-oxopurin-2-ylamino)-3-butene [MeSH Supplementary Concept]
- 4-chlorotamoxifen [MeSH Supplementary Concept]
- 4-fluorotamoxifen [MeSH Supplementary Concept]
- 4-hydroxy-N-desmethyltamoxifen [MeSH Supplementary Concept]
- 4-hydroxyospemifene [MeSH Supplementary Concept]
- 4-hydroxytamoxifen beta-glucuronide [MeSH Supplementary Concept]
- 4-hydroxytoremifene [MeSH Supplementary Concept]
- 4-iodo-tamoxifen [MeSH Supplementary Concept]
- 4-methyltamoxifen [MeSH Supplementary Concept]
- 6,7-dihydro-8-phenyl-9-(4-(2-(dimethylamino)ethoxy)phenyl)-5-H-benzocycloheptene [MeSH Supplementary Concept]
- ACFT protocol [MeSH Supplementary Concept]
- ACT regimen [MeSH Supplementary Concept]
- AVCT protocol [MeSH Supplementary Concept]
- CAMFTP protocol [MeSH Supplementary Concept]
- CAPT protocol [MeSH Supplementary Concept]
- CDPTH regimen [MeSH Supplementary Concept]
- CEFT protocol [MeSH Supplementary Concept]
- CMFPT protocol [MeSH Supplementary Concept]
- CMFPTH regimen [MeSH Supplementary Concept]
- DAT protocol 2 [MeSH Supplementary Concept]
- DAVTH protocol [MeSH Supplementary Concept]
- DAVTHML regimen [MeSH Supplementary Concept]
- DBCT protocol [MeSH Supplementary Concept]
- DBPT protocol [MeSH Supplementary Concept]
- DBPT regimen [MeSH Supplementary Concept]
- FCT protocol [MeSH Supplementary Concept]
- GSK5182 [MeSH Supplementary Concept]
- H 1285 [MeSH Supplementary Concept]
- ICI 142269 [MeSH Supplementary Concept]
- ICI 145680 [MeSH Supplementary Concept]
- MT protocol [MeSH Supplementary Concept]
- MTF protocol [MeSH Supplementary Concept]
- N,N-didesmethyl-4-hydroxytamoxifen [MeSH Supplementary Concept]
- N,N-didesmethyltamoxifen [MeSH Supplementary Concept]
- N-(2-chloroethyl)-2-(4-(1,2-diphenylbutenyl)phenoxy)ethyl carbamate [MeSH Supplementary Concept]
- N-(2-chloroethyl)-N'-2-(4-(1,2-diphenylbutenyl)phenoxy)ethyl-N-nitrosourea [MeSH Supplementary Concept]
- N-(2-chloroethyl)-N-nitroso-2-(4-(1,2-diphenylbutenyl)phenoxy)ethyl carbamate [MeSH Supplementary Concept]
- N-(7-nitrobenzo(c)(1,2,5)oxadiazol-4-yl)demethyltamoxifen [MeSH Supplementary Concept]
- N-demethyldroloxifene [MeSH Supplementary Concept]
- N-desmethyltamoxifen [MeSH Supplementary Concept]
- N-desmethyltoremifene [MeSH Supplementary Concept]
- PAFT protocol [MeSH Supplementary Concept]
- PFT protocol [MeSH Supplementary Concept]
- TAD protocol [MeSH Supplementary Concept]
- TAP protocol [MeSH Supplementary Concept]
- TAT 59 [MeSH Supplementary Concept]
- TEMP protocol [MeSH Supplementary Concept]
- afimoxifene [MeSH Supplementary Concept]
- alpha,4-dihydroxytamoxifen [MeSH Supplementary Concept]
- alpha-(N(2)-deoxyguanosinyl)tamoxifen [MeSH Supplementary Concept]
- alpha-(N(2)-deoxyguanosinyl)tamoxifen N-oxide [MeSH Supplementary Concept]
- alpha-(N(6)-deoxyadenosinyl)tamoxifen [MeSH Supplementary Concept]
- alpha-(deoxyguanosin-N(2)-yl)-N,N-didesmethyltamoxifen [MeSH Supplementary Concept]
- alpha-acetoxytamoxifen [MeSH Supplementary Concept]
- alpha-hydroxy-N,N-didesmethyltamoxifen [MeSH Supplementary Concept]
- alpha-hydroxytamoxifen [MeSH Supplementary Concept]
- alpha-sulfate tamoxifen [MeSH Supplementary Concept]
- boroxifen [MeSH Supplementary Concept]
- desdimethyltamoxifen [MeSH Supplementary Concept]
- dihydrotamoxifen [MeSH Supplementary Concept]
- droloxifene [MeSH Supplementary Concept]
- ethylbromide tamoxifen [MeSH Supplementary Concept]
- fispemifene [MeSH Supplementary Concept]
- homotamoxifen aziridine [MeSH Supplementary Concept]
- idoxifene [MeSH Supplementary Concept]
- indometafen [MeSH Supplementary Concept]
- iododesethyltamoxifen aziridine [MeSH Supplementary Concept]
- iodomethyl-N,N-diethyltamoxifen [MeSH Supplementary Concept]
- iodotamoxifen [MeSH Supplementary Concept]
- isotretinoin embryopathy like syndrome [MeSH Supplementary Concept]
- ospemifene [MeSH Supplementary Concept]
- panomifene [MeSH Supplementary Concept]
- ridaifen G [MeSH Supplementary Concept]
- ridaifen-B [MeSH Supplementary Concept]
- ridaifen-F [MeSH Supplementary Concept]
- ridaifen-SB8 [MeSH Supplementary Concept]
- tamoxifen 1,2-epoxide [MeSH Supplementary Concept]
- tamoxifen N-oxide [MeSH Supplementary Concept]
- tamoxifen acid [MeSH Supplementary Concept]
- tamoxifen analog II [MeSH Supplementary Concept]
- tamoxifen aziridine [MeSH Supplementary Concept]
- tamoxifen catechol [MeSH Supplementary Concept]
- tamoxifen methiodide [MeSH Supplementary Concept]
- tamoxifen-pyropheophorbide conjugate [MeSH Supplementary Concept]
See also inter- (CISMeF)
- Product containing tamoxifen (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Product containing tamoxifen (medicinal product) [SNOMED CT concept]
- Tamoxifen [ICD-11 Extension code]
- Tamoxifen [NCIt concept]
- Tamoxifen [LOINC component]
- Tamoxifen (substance) [SNOMED CT concept]
- tamoxifen [ATC Code]
- tamoxifen [Substance BNPC]
- tamoxifen [SNOMED Notion]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients